of drug cost. Results No significant differences in non--adherence between intervention and control groups were found for medications with low price and low patient maximum coinsurance, such as antiplatelet and beta--blockers. For ACEI/ARB and statins, the change had an immediate effect in the proportion of non--adherence in the pensioner group as compared with the control group (6.8% and 8.3% increase respectively, p<0.01 for both). Non--adherence to statins significantly increased after the reform for the middle to high income group vs. control group (7.8% increase, p<0.01). However, those effects were transitory. Conclusions Coinsurance changes may lead to increased non--adherence to proven, effective therapies, especially for higher priced agents with higher patient cost share. Adherence was already sub--optimal before the cost--sharing policy change, with a clear cost / income gradient. Consideration should be given to fully exempt high risk patients from drug cost--sharing.
